Journal article
Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.
Abstract
PATIENTS AND METHODS: We conducted a randomized, multicenter study of intravenous cyclophosphamide 500 mg/m2 plus fluorouracil 500 mg/m2 combined with either mitoxantrone (Novantrone, Lederle Cyanamid Canada Ltd, Willowdale, Ontario) 10 mg/m2 (CNF) or doxorubicin (Adriamycin, Adria Laboratories of Canada Ltd, Mississauga, Ontario) 50 mg/m2 (CAF) every 3 weeks in advanced breast cancer.
RESULTS: The response rate in 249 randomized patients was …
Authors
Stewart DJ; Evans WK; Shepherd FA; Wilson KS; Pritchard KI; Trudeau ME; Wilson JJ; Martz K
Journal
Journal of Clinical Oncology, Vol. 15, No. 5, pp. 1897–1905
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 1997
DOI
10.1200/jco.1997.15.5.1897
ISSN
0732-183X